crc

ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
Exploiting the gut microbiome for cancer diagnosis and treatment
ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
Clinical implications of intra-tumour heterogeneity in colon cancer
Region-based biomarkers.
Clinical implications of intra-tumour heterogeneity in colon cancer
Colobiome: Tumour-adjacent microbiome and immune profile of tumour in the context of heterogeneity and aggressivness of colorectal cancer
The aim is to improve prognostic and predictive stratification of CRC by defining microbial-immune-molecular CRC pathophenotypes and correlate them with tumour aggressiveness and patient prognosis.
Colobiome: Tumour-adjacent microbiome and immune profile of tumour in the context of heterogeneity and aggressivness of colorectal cancer
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.
Clinical trial for cMET inhibitor
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.